Vivos Therapeutics (VVOS)
(Delayed Data from NSDQ)
$4.13 USD
+1.33 (47.50%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $4.19 +0.06 (1.45%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Vivos Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 14 | 16 | 17 | 13 | 11 |
Cost Of Goods | 6 | 6 | 4 | 3 | 3 |
Gross Profit | 8 | 10 | 13 | 10 | 9 |
Selling & Adminstrative & Depr. & Amort Expenses | 26 | 35 | 33 | 22 | 19 |
Income After Depreciation & Amortization | -17 | -25 | -20 | -12 | -11 |
Non-Operating Income | 4 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -14 | -24 | -20 | -12 | -11 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -24 | -20 | -12 | -11 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -14 | -24 | -20 | -12 | -11 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -17 | -24 | -20 | -11 | -10 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -17 | -25 | -20 | -12 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.22 | 0.92 | 0.85 | 0.52 | NA |
Diluted EPS Before Non-Recurring Items | -13.03 | -26.00 | -24.00 | -35.00 | NA |
Diluted Net EPS (GAAP) | -11.14 | -26.00 | -24.00 | -35.00 | NA |
Fiscal Year end for Vivos Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 4.05 | 3.42 | 3.25 | 3.30 | 3.40 |
Cost Of Goods | 1.40 | 1.48 | 1.31 | 1.40 | 1.30 |
Gross Profit | 2.65 | 1.94 | 1.94 | 1.90 | 2.10 |
SG&A, R&D, and Dept/Amort Expenses | 4.59 | 5.73 | 6.22 | 5.39 | 6.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.94 | -3.79 | -4.28 | -3.49 | -4.52 |
Non-Operating Income | 0.01 | 0.02 | -0.12 | 1.40 | -1.01 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1.93 | -3.76 | -4.26 | -2.09 | -5.53 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.93 | -3.76 | -4.26 | -2.09 | -5.53 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.93 | -3.76 | -4.26 | -2.09 | -5.53 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3.23 | 2.31 | 1.22 | 1.20 | 1.20 |
Diluted EPS Before Non-Recurring Items | -0.60 | -1.63 | -3.05 | -1.75 | -3.75 |
Diluted Net EPS (GAAP) | -0.60 | -1.63 | -3.14 | -1.75 | -4.50 |